# A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT07490301** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 900 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- PDAC

## Interventions

- **DRUG:** Telisotuzumab adizutecan
- **DRUG:** Fluorouracil
- **DRUG:** Folinic acid/ Leucovorina
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT07490301
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-03
- **Primary completion:** 2031-06
- **Final completion:** 2031-06
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490301, "A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07490301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*